about
Yellow fever vaccines and international travelersRacial/Ethnic and social class differences in preventive care practices among persons with diabetesSocial and demographic predictors of no transport prior to premature cardiac death: United States 1999-2000.Muslim patients and health disparities in the UK and the USFilariasis in travelers presenting to the GeoSentinel Surveillance Network.Antibiotic resistance and choice of antimicrobial agents for acute otitis media.Preventing infectious diseases during and after international adoption.Characteristics and spectrum of disease among ill returned travelers from pre- and post-earthquake Haiti: The GeoSentinel experience.GeoSentinel surveillance of illness in returned travelers, 2007-2011Optimization of the cutoff value for a commercial anti-dengue virus IgG immunoassay.Yellow fever: epidemiology and prevention.Travel-associated illness trends and clusters, 2000-2010.Travel case scenarios as a demonstration of risk assessment of VFR travelers: introduction to criteria and evidence-based definition and framework.The visiting friends or relatives traveler in the 21st century: time for a new definition.Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).Multicenter study to evaluate the OptiMAL test for rapid diagnosis of malaria in U.S. hospitalsLatitudinal patterns of travel among returned travelers with influenza: results from the GeoSentinel Surveillance Network, 1997-2007.Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network.Travel-associated sexually transmitted infections: an observational cross-sectional study of the GeoSentinel surveillance database.Health challenges of young travelers visiting friends and relatives compared with those traveling for other purposes.Vaccine administration decision making: the case of yellow fever vaccine.Infectious disease screening for refugees resettled in the United States.The problem of resistant bacteria for the management of acute otitis media.Serious bacterial infections in febrile infants and children selected for lumbar puncture.Therapy for acute otitis media. Preference of parents for oral or parenteral antibiotic.Children and international travel: immunizations.Use of oral cephalosporins in infants and children.Stability of chloroquine in an extemporaneously prepared suspension stored at three temperatures.Evaluation of a rapid qualitative enzyme chromatographic test for glucose-6-phosphate dehydrogenase deficiencyPediatric travel medicine: challenges for the primary care and travel medicine specialist.Spectrum of illness in international migrants seen at GeoSentinel clinics in 1997-2009, part 1: US-bound migrants evaluated by comprehensive protocol-based health assessment.Reported use of antimicrobial agents in children attending a pediatric emergency department.Reappraising newborn eye care.Role of immigrants and migrants in emerging infectious diseases.Pneumococcal vaccine for Olympic athletes and visitors to Spain.Prevention of travel-related infectious diseases in families of internationally adopted children.Meningococcal disease among children who live in a large metropolitan area, 1981-1996.Comparison of varicella history with presence of varicella antibody in refugees.Otitis media in children born to human immunodeficiency virus-infected mothers.Intrapulmonary percussive ventilation vs incentive spirometry for children with neuromuscular disease.
P50
Q22305943-3851C09C-8127-4FEB-B385-4FBC1A3652B3Q33260936-2F277E92-44BF-4D14-A7A0-3A87D9C616E5Q33263690-B4B543A2-D64B-48F3-9B67-AA133CEC8661Q33300311-535DE257-6CF7-45AC-8EBC-4B1793B7C551Q33312446-71948318-4012-45F3-8689-AA00A55A4434Q35034939-AB933287-FA0B-45BE-B537-F0688870E24DQ35215889-233744FB-E859-47B7-A572-2953A4641916Q35636992-06D4CC95-3FA9-41E4-9C64-06F49811298CQ36239501-69B64489-3E8E-489C-B9A7-3FEB938EEC9CQ36668546-79B043AA-B487-488D-8A68-AC87933AFD77Q36737214-C7F00B7B-629D-4141-B264-4D99E855E260Q37021081-14D37C2F-9AC4-4804-94E9-790D5A8072A6Q37764063-8D1077D0-1104-4D4B-BA98-4413F7AFBC83Q37764064-6A0C3744-A213-407C-801B-3A64F38BDDB0Q38051944-D3D6F96C-5830-4CFF-92FC-DA5CE88198FFQ38463998-D8E9F5D4-77EA-4B3D-B7EC-3574676D9D29Q38913228-E5C661F6-0956-4016-92BA-7DF8DD77885AQ38913240-6B79B13A-2FD7-4BB9-9878-6C32D19ADBBEQ39226071-41AF9B5A-95DD-4E6F-9636-E8D1A5119783Q40277473-E03A4CF3-F480-4591-A274-1D84675414D6Q40284448-536C336A-A28C-4AF4-A939-41988DFC04D7Q40477056-2A298D76-CD87-4775-B198-698860C62283Q40531570-D1CB3A77-709E-4BA5-9E05-583544587F3AQ40694590-9B828108-943D-446C-9F5A-C838BAF7827CQ40945561-FA0E7848-A5C7-4DB0-9264-1C1C9FB4E4CFQ40960228-5B572B02-2981-4A73-AD1D-F43734AB8BD7Q41504327-817C53AA-F898-4855-9CB8-83318936DAE4Q41934793-99BDD90A-1507-41B2-9AFA-A133CC01C46CQ42025500-CA82AD17-A069-4C5E-A8DA-F4A3910FEACFQ42269531-3A05F20F-0A40-47EF-8B53-FC4F40F97243Q42283323-75429E85-3F19-4F90-AB64-E87984C38DE7Q43414932-181B92FD-8FFD-4FDA-AA0F-F5E187CE0F7CQ43424780-2B720B5F-D8E4-43F2-9F63-A731AFAEAF20Q43835088-CF2739FC-63DB-412A-B4C4-217A9883D8C2Q44152737-BC7DF15F-225B-481C-96D2-4E7C01C4960DQ44773953-9EABA58E-0A89-4C75-B14D-7A2C0CE9C814Q44814483-63C61AC2-95B8-4598-87C9-A74BB9319756Q45061405-93F736C6-2CAC-4276-BCB1-C092026FD3D5Q45232693-5773C341-C9C0-4635-9003-C458F34F7682Q46531421-4157A520-A654-479A-946B-31690D3E8555
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Elizabeth D Barnett
@ast
Elizabeth D Barnett
@en
Elizabeth D Barnett
@es
Elizabeth D Barnett
@sl
type
label
Elizabeth D Barnett
@ast
Elizabeth D Barnett
@en
Elizabeth D Barnett
@es
Elizabeth D Barnett
@sl
prefLabel
Elizabeth D Barnett
@ast
Elizabeth D Barnett
@en
Elizabeth D Barnett
@es
Elizabeth D Barnett
@sl
P106
P21
P31
P496
0000-0003-4822-5949